Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relaxin is a naturally occurring peptide hormone, structurally related to insulin, with a molecular weight of about 6000 Da. It is primarily produced by the corpus luteum in females and also found in males. In pregnancy, relaxin plays a key role in reproductive physiology by relaxing the uterine muscle and loosening pelvic ligaments to facilitate childbirth. Beyond reproduction, relaxin acts as a potent vasodilator through activation of nitric oxide pathways and other signaling cascades (such as PI3K/Akt and VEGF), leading to increased cardiac output and renal perfusion. These properties have led to its investigation as a treatment for acute heart failure, where it has shown favorable trends in early clinical trials[3][7][8]. Relaxin exerts its effects mainly via G protein-coupled receptors known as relaxin family peptide receptors (RXFP1-4), with RXFP1 being the primary receptor mediating cardiovascular actions[6][8]. Recombinant forms such as serelaxin have been developed for therapeutic use[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Relaxin.